Propranolol hydrochloride

RP-HPLC method has been developed for the quantitative estimation of Propranolol hydrochloride and Etizolam using C 18 column and a mobile phase consisting of Methanol and Water in the ratio 70:30. The mobile phase was pumped at a rate of 1ml/min and detection was carried out at 281.5 nm(iso-absorptive point). The linearity was found to be in range of 5-50µg/ml and 0.5-5µg/ml with regression coefficient (r2=0.999, and r2=0.997) for Propranolol hydrochloride and Etizolam respectively. The peaks obtained were sharp having baseline separation with a retention time of 2.35and 6.57min for Propranolol hydrochloride and Etizolam respectively.The LOD was found to be at the concentration of0.1µg/ml and 0.025µg/ml for Propranolol hydrochloride and Etizolam respectively. The percentage recovery was found to be 98.5% to 100.58% for Propranololhydrochloride and 95% to 106.6% for Etizolam. The method was validated statistically.

Oral drug delivery has been known for decades as the most widely utilized route of administration among all the routes. United State Food and Drug Administration (FDA) defined ODT as “a solid dosage form containing medicinal substance or active ingredients which disintegrate rapidly usually within a matter of second when placed upon the tongue. Propranolol is a nonselective beta-adrenergic blocker and is almost completely absorbed following oral administration. However , most of drug is undergoes high first-pass metabolism by the liver and on average, only about 25% of propranolol reaches the systemic circulation. The present study investigated to development of novel fast dissolving tablet of Propranolol HCL which was by first pass metabolism, provide rapid onset of action and increasing the bioavailability of the drug. The fast dissolving tablets were prepared by Direct compression method by using different superdisintegrant like Crosspovidone, crosscarmellose sodium, sodium starch glycolate etc. The advantage of this formulation is such that in case of hypertension attack patient can take the drug without the usage of water. Therefore the main objective of the present work is to develop orodispersible tablets of Propranolol hydrochloride to improve bioavailability, disintegration time, dissolution efficacy and patient compliance.